SCHEMBL23212260

SCHEMBL23212260

C=C(c1ccccc1)c1cn(C)c(=O)c2c(C(=O)OC)coc12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.49
NR4A2 P43354 4/20 0.41
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 2/20 0.38
THRB P10828 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA3 P34903 1/20 0.37
SLC6A3 Q01959 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.35
TP53 P04637 2/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28723227 0.89 BRD4 (0.37) BRD4ALDH1A1KDM4ELMNAKMT2A
SCHEMBL23233906 0.76 BRD4 (0.45) BRD4NR4A2ALDH1A1KDM4ELMNA
SCHEMBL27214874 0.76 BRD4 (0.45) BRD4NR4A2ALDH1A1KDM4ELMNA
SCHEMBL23212251 0.75 BRD4 (0.44) BRD4NR4A2ALDH1A1KDM4ELMNA
SCHEMBL23212499 0.73 BRD4 (0.42) BRD4ALDH1A1KDM4EKMT2AMEN1
SCHEMBL13101770 0.70 TSHR (0.59) ALDH1A1KDM4ELMNATSHRKMT2A
SCHEMBL22729479 0.67 BRD4 (0.55) BRD4NR4A2ALDH1A1KDM4ELMNA
SCHEMBL22729613 0.65 NOTUM (0.34) BRD4KDM4ELMNAHSD17B10L3MBTL1
SCHEMBL28719291 0.64 MAP2K1 (0.34) BRD4L3MBTL1
SCHEMBL21056865 0.63 KDM4E (0.53) ALDH1A1KDM4ELMNATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150343-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2024-05-09 US disclosed
EP-4043462-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF Haihe Biopharma Co., Ltd. (CN) 2022-08-17 EP disclosed
WO-2021068755-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 上海海和药物研究开发股份有限公司 2021-04-15 WO disclosed
WO-2021068755-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 上海海和药物研究开发股份有限公司 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150343-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF BRD4, BICRA, BET1 BRD4 1/4885NR4A2 1161/4885ALDH1A1 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.